{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:41:49Z","timestamp":1791121309427,"version":"4.1.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>LBM415 (NVP PDF-713) is the first member of the peptide deformylase (PDF) inhibitor class being developed for clinical trials as a parenteral and oral agent for treatment of community-acquired respiratory tract disease and serious infections caused by antimicrobial-resistant gram-positive cocci. In this study susceptibility testing results from 1,306 recent clinical isolates selected to overrepresent resistance trends among the species were summarized. All staphylococci (153 strains; MIC at which 90% of isolates were inhibited [MIC<jats:sub>90<\/jats:sub>], 2 \u03bcg\/ml),<jats:italic>Streptococcus pneumoniae<\/jats:italic>(170 strains; MIC<jats:sub>90<\/jats:sub>, 1 \u03bcg\/ml), other streptococci (150 strains; MIC<jats:sub>90<\/jats:sub>, 1 \u03bcg\/ml), enterococci (104 strains; MIC<jats:sub>90<\/jats:sub>, 4 \u03bcg\/ml),<jats:italic>Moraxella catarrhalis<\/jats:italic>(103 strains; MIC<jats:sub>90<\/jats:sub>, 0.5 \u03bcg\/ml), and<jats:italic>Legionella pneumophila<\/jats:italic>(50 strains; MIC<jats:sub>90<\/jats:sub>, 0.12 \u03bcg\/ml) were inhibited at \u22648 \u03bcg of LBM415\/ml, as were 97% of<jats:italic>Haemophilus influenzae<\/jats:italic>isolates (300 strains; MIC<jats:sub>90<\/jats:sub>, 4 to 8 \u03bcg\/ml). Among other bacterial groups, 100% of gram-positive and -negative anaerobes, including 22<jats:italic>Bacteroides<\/jats:italic>spp. strains (31 strains total; MIC<jats:sub>90<\/jats:sub>, 1 \u03bcg\/ml), were inhibited by \u22644 \u03bcg\/ml, whereas<jats:italic>Enterobacteriaceae<\/jats:italic>(112 strains) and most nonfermentative bacilli (107 strains) were not inhibited at readily achievable concentrations. The compound was found to have a dominantly bacteriostatic action, and spontaneous single-step mutational rates occurred at low levels (10<jats:sup>\u22126<\/jats:sup>to &lt;10<jats:sup>\u22128<\/jats:sup>). Drug interaction studies failed to identify any class-specific synergistic interactions, nor were antagonistic interactions observed. Variations in broth and agar MIC test conditions demonstrated that, whereas the agar-based method trended towards a 1-log<jats:sub>2<\/jats:sub>dilution-higher MIC than the broth method and was inoculum dependent, other variations in incubation environment, medium supplements, pH, or calcium concentration had little influence on LBM415 MIC results. Use of the efflux inhibitor phe-arg-\u03b2-naphthylamide showed an average of 1 log<jats:sub>2<\/jats:sub>dilution decrease in<jats:italic>H<\/jats:italic>.<jats:italic>influenzae<\/jats:italic>MICs, demonstrating the contribution of efflux pumps in influencing susceptibility to PDF inhibitors. The in vitro activity of LBM415 against targeted bacterial species, including resistant subsets, and other laboratory characteristics of this novel compound demonstrate the potential of PDF inhibitors as a new class of antimicrobial agents.<\/jats:p>","DOI":"10.1128\/aac.49.4.1468-1476.2005","type":"journal-article","created":{"date-parts":[[2005,3,25]],"date-time":"2005-03-25T19:23:13Z","timestamp":1111778593000},"page":"1468-1476","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":56,"title":["Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance"],"prefix":"10.1128","volume":"49","author":[{"given":"Thomas R.","family":"Fritsche","sequence":"first","affiliation":[{"name":"The JONES Group\/JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"The JONES Group\/JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Cleeland","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corp., East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"The JONES Group\/JMI Laboratories, North Liberty, Iowa"},{"name":"Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(68)90307-0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00114-6"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0732-8893(03)00162-7","volume":"48","year":"2004","unstructured":"Anderegg, T. R., R. N. Jones, and The Quality Control Working Group. 2004. Disk diffusion quality control guidelines for NVP PDF-713: a novel peptide deformylase inhibitor. Diagn. Microbiol. Infect. Dis.48:55-57.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1058-1064.2001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.1.1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0924-8579(03)00246-2","volume":"22","year":"2003","unstructured":"Bowker, K. E., A. R. Noel, and A. P. McGowan. 2003. In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int. J. Antimicrob. Agents22:557-561.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi992245y"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.563-570.2001"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.4033-4036.2004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2003.00765.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.4027-4032.2004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1198-743X.2004.00946.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1046\/j.1365-2958.2000.01908.x","volume":"36","year":"2000","unstructured":"Giglione, C., M. Pierre, and T. Meinnel. 2000. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol. Microbiol.36:1197-1205.","journal-title":"Mol. Microbiol."},{"key":"e_1_3_2_15_2","first-page":"701","volume":"195","year":"1962","unstructured":"Gordon, J. J., B. K. Kelly, and G. A. Miller. 1962. Actinonin: an antibiotic substance produced by an actinomycete. Nature195:701-702.","journal-title":"Nature"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.2752-2764.2002"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1148-1150.2003"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-37923"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/jac\/dkg055","volume":"51","year":"2003","unstructured":"Jones, R. N., and P. R. Rhomberg. 2003. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J. Antimicrob. Chemother.51:157-161.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.12.005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh184"},{"key":"e_1_3_2_22_2","unstructured":"Knapp C. and J. A. Moody. 1992. Tests to assess bactericidal activity section 5.16. In H. D. Isenberg (ed.) Clinical microbiology procedures handbook. ASM Press Washington D.C."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/bi00829a059","volume":"8","year":"1969","unstructured":"Livingstone, D. M., and P. Leder. 1969. Deformylation and protein synthesis. Biochemistry8:435-443.","journal-title":"Biochemistry"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2432-2435.2001"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1825-1831.2000"},{"key":"e_1_3_2_26_2","unstructured":"National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_27_2","unstructured":"National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing M100-S14. Supplemental tables. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_28_2","unstructured":"National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria 5th ed. Approved standard M11-A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_29_2","unstructured":"National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26A. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.4.697"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1447-1448.2003"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0960-894X(01)00242-6","volume":"11","year":"2001","unstructured":"Thorarensen, A., M. R. Deibel, Jr., D. C. Rhorer, A. F. Vosters, A. W. Yem, V. D. Marshall, J. C. Lynn, M. J. Bohanon, P. K. Tomich, G. E. Zurenko, M. T. Sweeney, R. M. Jensen, J. W. Nielsen, E. P. Seest, and L. A. Dolak. 2001. Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Bioorg. Med. Chem. Lett.11:1355-1358.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"e_1_3_2_33_2","first-page":"785","volume":"5","year":"2002","unstructured":"Waller, A. S., and J. M. Clements. 2002. Novel approaches to antimicrobial therapy: peptide deformylase. Curr. Opin. Drug Discov. Dev.5:785-792.","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1117-1118.2002"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(01)01925-0"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.4.1468-1476.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.4.1468-1476.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T09:05:47Z","timestamp":1706087147000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.4.1468-1476.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1128\/AAC.49.4.1468-1476.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.4.1468-1476.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"2004-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}